ConductScience.org, home

Paper9448657

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

Marder SR and 2 others. J Clin Psychiatry, 1997. Cited by 683 papers, by iCite.

Cite this record

ConductScience Library. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Papers, record 9448657. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9448657

Download JSON
Disease
schizophrenia345 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.
PubMed
Journal
J Clin Psychiatry
PubMed
Year
1997
PubMed
Publication types
Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
683
iCite
Relative citation ratio, by iCite
24.1
iCite
Revised in PubMed
2025-11-25
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Marder SRS R
2Davis JMJ M
3Chouinard GG

Source PubMed

Download CSV of authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
RisperidoneMajor topic
SchizophreniaMajor topic
Schizophrenic PsychologyMajor topic
Adolescent
Adult
Aged
Basal Ganglia Diseases
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Factor Analysis, Statistical
Female
Haloperidol
Humans
Male
Middle Aged
Placebos
Psychiatric Status Rating Scales
Schizophrenia, Paranoid
Severity of Illness Index
Treatment Outcome

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00249132A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic SchizophreniaResults

Source ClinicalTrials.gov

Download CSV of trials

Cited by241

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 683 citations.

PMIDTitleJournalYearIn PapersSource
42936181The Effects of Erratic Ratings on Placebo Response and Signal Detection in the Roche Bitopertin Phase 3 Negative Symptom Studies-A Post Hoc Analysis.Schizophr Bull Open2020https://conductscience.org/library/papers/42936181PubMed
42936133Issues and Perspectives in Designing Clinical Trials for Negative Symptoms in Schizophrenia: Consensus Statements.Schizophr Bull Open2020https://conductscience.org/library/papers/42936133PubMed
42922680Longitudinal Brain Correlates of Cognitive Performance in Early Psychosis.medRxiv2026https://conductscience.org/library/papers/42922680PubMed
42761248Beyond single-person paradigms: N400 alterations in a social context in schizophrenia.Front Psychiatry2026https://conductscience.org/library/papers/42761248PubMed
42706283Revisiting symptom dimensions in schizophrenia with exploratory graph analysis.Schizophrenia (Heidelb)2026https://conductscience.org/library/papers/42706283PubMed
42621264The mechanism of action and clinical efficacy of xanomeline-trospium in schizophrenia: A comprehensive review.Ther Adv Psychopharmacol2026https://conductscience.org/library/papers/42621264PubMed
42401715Diagnostic and sex effects on frontostriatal brain wiring structural organization in early psychosis affective subjects compared to healthy controls.Mol Psychiatry2026https://conductscience.org/library/papers/42401715PubMed
42356009Sharp-Wave EEG Activity and Cytomegalovirus Exposure in Schizophrenia Spectrum Disorders: A Neuroimmune Perspective.J Clin Med2026https://conductscience.org/library/papers/42356009PubMed
42123174Association of Depressive and Negative Symptoms with Quality of Life in Schizophrenia: A Cross-Sectional Inpatient Study.J Clin Med2026https://conductscience.org/library/papers/42123174PubMed
42111925Assessment of serum inflammatory cytokines in first-episode psychosis: Cross-sectional study.S Afr J Psychiatr2026https://conductscience.org/library/papers/42111925PubMed
42018313Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized Clinical Trial.JAMA Psychiatry2026https://conductscience.org/library/papers/42018313PubMed
42011073
Quality of life in early-phase schizophrenia patients starting treatment with long-acting injectable vs. oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST).
Eur Psychiatry2026https://conductscience.org/library/papers/42011073PubMed
41800547High-density EEG study in patients with schizophrenia treated with cariprazine.Int J Neuropsychopharmacol2026https://conductscience.org/library/papers/41800547PubMed
41597316Prevalence of Primary, Prominent, and Predominant Negative Symptoms of Schizophrenia in Routine Inpatient Psychiatric Care.Medicina (Kaunas)2025https://conductscience.org/library/papers/41597316PubMed
41388146Rate and predictors of remission and recovery in first-episode psychosis: A 12-year follow-up of randomized-controlled trial on early intervention.Mol Psychiatry2026https://conductscience.org/library/papers/41388146PubMed
41384453Confirmatory factor analysis of competing PANSS negative symptom models: data from OPTiMiSE first-episode schizophrenia study.BJPsych Open2025https://conductscience.org/library/papers/41384453PubMed
41369302The effects of lurasidone on five symptom domains and individual items in schizophrenia: Post-hoc analysis from Phase 3 study.Int Clin Psychopharmacol2026https://conductscience.org/library/papers/41369302PubMed
41321712Psychometric Properties and Factor Structure of the Arabic Translation of the Brief Negative Symptom Scale.Complex Psychiatry2025https://conductscience.org/library/papers/41321712PubMed
41311559Quantifying Exploratory Behavior In The Human Behavioral Pattern Monitor Using Automated Video Tracking.Meth Psychol2025https://conductscience.org/library/papers/41311559PubMed
41272239Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with Schizophrenia.CNS Drugs2026https://conductscience.org/library/papers/41272239PubMed

See all 241 cited byDownload CSV of cited by

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
HALOPERIDOLCHEMBL54Results1https://conductscience.org/library/drugs/CHEMBL54ChEMBL
RISPERIDONECHEMBL85Results1https://conductscience.org/library/drugs/CHEMBL85ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9448657

GET https://conductscience.org/api/papers/v1/9448657/cited_by?page=2